ABCC6 deficiency and bone loss: A double benefit of etidronate for patient presenting with pseudoxanthoma elasticum?

Saved in:
Bibliographic Details
Published in:Experimental dermatology 2022-10, Vol.31 (10), p.1635-1637
Main Authors: Kauffenstein, Gilles, Chappard, Daniel, Leftheriotis, Georges, Martin, Ludovic
Format: Article
Language:English
Subjects:
ABCC6
ageing
Bioengineering
Bone Diseases, Metabolic
Bone loss
Etidronic acid
Etidronic Acid - therapeutic use
Humans
Life Sciences
Multidrug Resistance-Associated Proteins - genetics
Mutation
Pseudoxanthoma Elasticum - drug therapy
Pseudoxanthoma Elasticum - genetics
PXE
pyrophosphate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3526-f914d9b9d8e5b161fe6a5fc627daa05497dc829673e9c1df8aa46a0fb3156ce53
cites cdi_FETCH-LOGICAL-c3526-f914d9b9d8e5b161fe6a5fc627daa05497dc829673e9c1df8aa46a0fb3156ce53
container_end_page 1637
container_issue 10
container_start_page 1635
container_title Experimental dermatology
container_volume 31
creator Kauffenstein, Gilles
Chappard, Daniel
Leftheriotis, Georges
Martin, Ludovic
description
doi_str_mv 10.1111/exd.14636
format article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04022382v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2720311164</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3526-f914d9b9d8e5b161fe6a5fc627daa05497dc829673e9c1df8aa46a0fb3156ce53</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhi0EokvhwB9AlrjAIa0_YjvhgrZLaZFW4gISN8uxx6yrJA6x03b_PS7bFgkJX0aynnln7Aeh15Sc0HJO4dad0Fpy-QStqCSkIpKJp2hFWiIrqYg4Qi9SuiKEKq7Ec3TEhVKUMr5CeX222UjswAcbYLR7bEaHuzgC7mNKH_Aau7h0PeAOxgJlHD2GHNwcR5MB-zjjyeTSmvE0Qyo1jD_xTcg7PCVYXLw1Y97FwWDoTcrBLsPHl-iZN32CV_f1GH3_fP5tc1ltv1582ay3leWCycq3tHZt17oGREcl9SCN8FYy5Ywhom6Vsw1rpeLQWup8Y0wtDfEdp0JaEPwYvT_k7kyvpzkMZt7raIK-XG_13R2pCWO8Yde0sO8O7DTHXwukrIeQLPS9GSEuSTPZMNXUrG0K-vYf9Cou81heoplihBclsv473M7lI2fwjxtQou-06aJN_9FW2Df3iUs3gHskHzwV4PQA3IQe9v9P0uc_Ph0ifwPwAaC3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2720311164</pqid></control><display><type>article</type><title>ABCC6 deficiency and bone loss: A double benefit of etidronate for patient presenting with pseudoxanthoma elasticum?</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Kauffenstein, Gilles ; Chappard, Daniel ; Leftheriotis, Georges ; Martin, Ludovic</creator><creatorcontrib>Kauffenstein, Gilles ; Chappard, Daniel ; Leftheriotis, Georges ; Martin, Ludovic</creatorcontrib><identifier>ISSN: 0906-6705</identifier><identifier>EISSN: 1600-0625</identifier><identifier>DOI: 10.1111/exd.14636</identifier><identifier>PMID: 35771123</identifier><language>eng</language><publisher>Denmark: Wiley Subscription Services, Inc</publisher><subject>ABCC6 ; ageing ; Bioengineering ; Bone Diseases, Metabolic ; Bone loss ; Etidronic acid ; Etidronic Acid - therapeutic use ; Humans ; Life Sciences ; Multidrug Resistance-Associated Proteins - genetics ; Mutation ; Pseudoxanthoma Elasticum - drug therapy ; Pseudoxanthoma Elasticum - genetics ; PXE ; pyrophosphate</subject><ispartof>Experimental dermatology, 2022-10, Vol.31 (10), p.1635-1637</ispartof><rights>2022 The Authors. published by John Wiley &amp; Sons Ltd.</rights><rights>2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3526-f914d9b9d8e5b161fe6a5fc627daa05497dc829673e9c1df8aa46a0fb3156ce53</citedby><cites>FETCH-LOGICAL-c3526-f914d9b9d8e5b161fe6a5fc627daa05497dc829673e9c1df8aa46a0fb3156ce53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27900,27901</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35771123$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04022382$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Kauffenstein, Gilles</creatorcontrib><creatorcontrib>Chappard, Daniel</creatorcontrib><creatorcontrib>Leftheriotis, Georges</creatorcontrib><creatorcontrib>Martin, Ludovic</creatorcontrib><title>ABCC6 deficiency and bone loss: A double benefit of etidronate for patient presenting with pseudoxanthoma elasticum?</title><title>Experimental dermatology</title><addtitle>Exp Dermatol</addtitle><subject>ABCC6</subject><subject>ageing</subject><subject>Bioengineering</subject><subject>Bone Diseases, Metabolic</subject><subject>Bone loss</subject><subject>Etidronic acid</subject><subject>Etidronic Acid - therapeutic use</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Multidrug Resistance-Associated Proteins - genetics</subject><subject>Mutation</subject><subject>Pseudoxanthoma Elasticum - drug therapy</subject><subject>Pseudoxanthoma Elasticum - genetics</subject><subject>PXE</subject><subject>pyrophosphate</subject><issn>0906-6705</issn><issn>1600-0625</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kU1v1DAQhi0EokvhwB9AlrjAIa0_YjvhgrZLaZFW4gISN8uxx6yrJA6x03b_PS7bFgkJX0aynnln7Aeh15Sc0HJO4dad0Fpy-QStqCSkIpKJp2hFWiIrqYg4Qi9SuiKEKq7Ec3TEhVKUMr5CeX222UjswAcbYLR7bEaHuzgC7mNKH_Aau7h0PeAOxgJlHD2GHNwcR5MB-zjjyeTSmvE0Qyo1jD_xTcg7PCVYXLw1Y97FwWDoTcrBLsPHl-iZN32CV_f1GH3_fP5tc1ltv1582ay3leWCycq3tHZt17oGREcl9SCN8FYy5Ywhom6Vsw1rpeLQWup8Y0wtDfEdp0JaEPwYvT_k7kyvpzkMZt7raIK-XG_13R2pCWO8Yde0sO8O7DTHXwukrIeQLPS9GSEuSTPZMNXUrG0K-vYf9Cou81heoplihBclsv473M7lI2fwjxtQou-06aJN_9FW2Df3iUs3gHskHzwV4PQA3IQe9v9P0uc_Ph0ifwPwAaC3</recordid><startdate>202210</startdate><enddate>202210</enddate><creator>Kauffenstein, Gilles</creator><creator>Chappard, Daniel</creator><creator>Leftheriotis, Georges</creator><creator>Martin, Ludovic</creator><general>Wiley Subscription Services, Inc</general><general>Wiley</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope></search><sort><creationdate>202210</creationdate><title>ABCC6 deficiency and bone loss: A double benefit of etidronate for patient presenting with pseudoxanthoma elasticum?</title><author>Kauffenstein, Gilles ; Chappard, Daniel ; Leftheriotis, Georges ; Martin, Ludovic</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3526-f914d9b9d8e5b161fe6a5fc627daa05497dc829673e9c1df8aa46a0fb3156ce53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>ABCC6</topic><topic>ageing</topic><topic>Bioengineering</topic><topic>Bone Diseases, Metabolic</topic><topic>Bone loss</topic><topic>Etidronic acid</topic><topic>Etidronic Acid - therapeutic use</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Multidrug Resistance-Associated Proteins - genetics</topic><topic>Mutation</topic><topic>Pseudoxanthoma Elasticum - drug therapy</topic><topic>Pseudoxanthoma Elasticum - genetics</topic><topic>PXE</topic><topic>pyrophosphate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kauffenstein, Gilles</creatorcontrib><creatorcontrib>Chappard, Daniel</creatorcontrib><creatorcontrib>Leftheriotis, Georges</creatorcontrib><creatorcontrib>Martin, Ludovic</creatorcontrib><collection>Wiley-Blackwell Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Experimental dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kauffenstein, Gilles</au><au>Chappard, Daniel</au><au>Leftheriotis, Georges</au><au>Martin, Ludovic</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ABCC6 deficiency and bone loss: A double benefit of etidronate for patient presenting with pseudoxanthoma elasticum?</atitle><jtitle>Experimental dermatology</jtitle><addtitle>Exp Dermatol</addtitle><date>2022-10</date><risdate>2022</risdate><volume>31</volume><issue>10</issue><spage>1635</spage><epage>1637</epage><pages>1635-1637</pages><issn>0906-6705</issn><eissn>1600-0625</eissn><cop>Denmark</cop><pub>Wiley Subscription Services, Inc</pub><pmid>35771123</pmid><doi>10.1111/exd.14636</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0906-6705
ispartof Experimental dermatology, 2022-10, Vol.31 (10), p.1635-1637
issn 0906-6705
1600-0625
language eng
recordid cdi_hal_primary_oai_HAL_hal_04022382v1
source Wiley-Blackwell Read & Publish Collection
subjects ABCC6
ageing
Bioengineering
Bone Diseases, Metabolic
Bone loss
Etidronic acid
Etidronic Acid - therapeutic use
Humans
Life Sciences
Multidrug Resistance-Associated Proteins - genetics
Mutation
Pseudoxanthoma Elasticum - drug therapy
Pseudoxanthoma Elasticum - genetics
PXE
pyrophosphate
title ABCC6 deficiency and bone loss: A double benefit of etidronate for patient presenting with pseudoxanthoma elasticum?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-24T11%3A33%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ABCC6%20deficiency%20and%20bone%20loss:%20A%20double%20benefit%20of%20etidronate%20for%20patient%20presenting%20with%20pseudoxanthoma%20elasticum?&rft.jtitle=Experimental%20dermatology&rft.au=Kauffenstein,%20Gilles&rft.date=2022-10&rft.volume=31&rft.issue=10&rft.spage=1635&rft.epage=1637&rft.pages=1635-1637&rft.issn=0906-6705&rft.eissn=1600-0625&rft_id=info:doi/10.1111/exd.14636&rft_dat=%3Cproquest_hal_p%3E2720311164%3C/proquest_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3526-f914d9b9d8e5b161fe6a5fc627daa05497dc829673e9c1df8aa46a0fb3156ce53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2720311164&rft_id=info:pmid/35771123&rfr_iscdi=true